Selected Practices:
Insight
AI-Accelerated Breakthroughs: How AI is Reshaping the Future of Life Sciences
Joshua Y. Li
Principal, Life Science Strategy & InnovationFocus Area/Service
Life Sciences AdvisoryThe Royal Swedish Academy of Sciences’ decision to award Geoffrey Hinton, the “Godfather of AI,” and John Hopfield the 2024 Nobel Prize in Physics illuminated a profound truth: artificial intelligence has evolved from theoretical concept to a transformative force in scientific discovery. Their groundbreaking work in artificial neural networks did not just earn science’s highest honor, it validated AI’s power to revolutionize how we advance human knowledge.
This shift resonates deeply within Life Sciences, where AI accelerates everything from drug discovery to clinical trials. During a recent webinar, Josh Li, Principal, R&D Innovation at Acquis Consulting Group, and Michelle Wu, Cofounder & CEO of NyquistAI, presented insights that not only reveal how AI transforms the industry today, but also how it will reshape the future of pharma innovation.
The Dawn of a New AI Era
“Every time I read the news or developer forums, artificial intelligence has achieved a new frontier,” shared Wu. As someone with decades of experience in the Life Sciences industry, Michelle Wu has seen firsthand how the landscape evolved from viewing AI as a futuristic concept to an essential tool for innovation.
However, unlike other industries where companies can broadly apply AI solutions across R&D and commercialization processes, drug development demands nuance. Li put it succinctly: “In Life Sciences, assets and products in development must pass through multiple stage-gates in the biopharma value chain.” This peculiarity creates an opportunity for AI companies – like NyquistAI – to accelerate through stage-gates and provide specialized AI solutions that address the unique challenges of the pharma value chain.
Related: Transforming Pharma: Harnessing Artificial Intelligence in the Pharmaceutical Value Chain
Figure 1: Stage-Gates in the Pharma Value Chain
Meet the Players
Research and Early Science; Clinical Development, Clinical Operations, and Biostatistics; Regulatory Affairs, Quality, and Safety; CMC, Manufacturing, and Supply Chain; Medical Affairs; Commercial; and Governance and Board Operations define the key functional areas of the pharma value chain. AI products that specialize in accelerating function-specific activities can quantifiably save biopharma companies thousands – if not millions – in value by coordinating activities in a specific order to pass through each stage-gate.
Atomwise, Faro, ArisGlobal, Quartic.ai, ConcertAI, and Global Action Alliance are just a few of the players creating value in this space, using AI and machine learning for in-vitro analysis, clinical trial market assessments, regulatory advisory and guidance, quality control, systematic literature reviews, and deal sourcing and screening, among other areas.
Figure 2: Illustrative Use Cases and AI Companies in Functional Areas
However, even though innovation is within reach, many Life Sciences organizations are still finding their feet. A live poll revealed that only 13% of respondents consider themselves in the “transforming” stage of AI adoption, with the majority (38%) still experimenting.
Figure 3: Organizational Maturity Poll Results
What makes the results particularly intriguing is the ROI data presented during the webinar. When organizations implement NyquistAI’s solutions, the returns are staggering. Regulatory affairs use-cases have an 841% annualized ROI against the cost of annualized licenses. These are not just numbers – they represent real acceleration in bringing life-saving treatments to patients.
Figure 4: NyquistAI Use Cases and ROI
Breaking Through the Noise
The real breakthrough comes when organizations understand that success lies not in finding one perfect AI solution, but in creating what Li calls a “Composite Insight Hub” – a sophisticated network of AI solutions working together through custom workflows. Although Insight Hubs will require manual intervention in the beginning, Li believes this is the way to efficiently scale – and win. “[Composite Insight Hubs] are where the medium-sized companies will win, where the large companies will win, and where the small companies will win.”
2025 organizational budget allocations confirm this statement. According to a live poll, 50% of respondents plan to budget for AI applications in clinical operations, with clinical development, commercial, and medical affairs each claiming 33%. This breakdown demonstrates that organizations are not putting metaphorical eggs into one AI basket. Instead, companies are seeking to diversify AI investments across multiple functions.
Figure 5: 2025 AI Budget Allocations Poll Results
As Life Sciences organizations move into 2025, new use cases will likely emerge, specifically in clinical trial innovation, including protocol optimizations, digital twins, regulatory approvals, site selection, and patient recruitment and retention.
However, despite its ability to take Life Sciences organizations to a new level, AI isn’t a silver bullet. “There’s no magic button,” Wu emphasized. “You can’t just push it and have AI write your whole clinical protocol or FDA submission.” Yet, there is hope for what will come. “Right now, the innovation and adoption of AI is just scratching the surface.” Comparing AI to an iceberg, Wu continued by saying, “There’s ginormous potential under the sea levels that we haven’t even tapped into.”
The Road Ahead
As companies expand beyond experimentation to implementation, success will depend on finding the right balance between innovation and practicality. “Experiment, small experiment, quickly reiterate,” as Wu advises, but always with a clear vision of the intended value.
Life Sciences organizations are witnessing what could become the most significant transformation in how companies develop and deliver healthcare solutions. The Nobel Prize recognition might have been for physics, but the real revolution is happening in labs, clinical trials, and regulatory offices worldwide, where AI is quietly but fundamentally changing medical science advancement.
For those in the Life Sciences industry, the message is clear: the future belongs to those who can harness AI’s potential while maintaining a clear focus on practical, value-driven applications. Technology is ready – the question is, are we?
Acquis Consulting Group and NyquistAI have partnered to to streamline insight generation for Life Sciences organizations through expert advisory services and customized AI-powered solutions.